Comparison of contemporary risk scores in all groups of pulmonary hypertension - a PVRI GoDeep meta-registry analysis.

PVRI GoDeep meta-registry multicentric predictive power pulmonary hypertension risk stratification

Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
18 Mar 2024
Historique:
received: 14 11 2023
revised: 22 02 2024
accepted: 08 03 2024
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 20 3 2024
Statut: aheadofprint

Résumé

Pulmonary hypertension (PH) is a heterogeneous disease with poor prognosis. Accurate risk stratification is essential for guiding treatment decisions in pulmonary arterial hypertension (PAH). While various risk models were developed for PAH, their comparative prognostic potential requires further exploration. Additionally, the applicability of risk scores in PH groups beyond group 1 remains to be investigated. Are risk scores originally developed for PAH predictive in PH group 1-4? We conducted a comprehensive analysis of outcomes among incident PH patients enrolled in the multicenter worldwide PVRI-GoDeep meta-registry. Analyses were performed across PH groups 1-4 and further subgroups to evaluate the predictive value of PAH-risk scores, including REVEAL Lite 2, REVEAL 2.0, ESC/ERS 2022, COMPERA 3-strata and COMPERA 4-strata. 8565 patients were included in the study, of whom 3537 patients were assigned to group 1 PH while 1807, 1635, and 1586 patients were diagnosed with group 2, group 3, and group 4 PH. Pulmonary hemodynamics were impaired with median mPAP of 42 [33,52]mmHg and PVR of 7 [4,11]WU. All risk scores were prognostic in the entire PH population and in each of the PH groups 1-4. The REVEAL scores, when used as continuous prediction models, possessed the highest statistical prognostic power and granularity; the COMPERA 4-strata risk score provided sub-differentiation of the intermediate-risk group. Similar results were obtained when separately analyzing various subgroups (PH subgroups 1.1, 1.4.1, 1.4.4; 3.1, 3.2; group 2 with isolated post-capillary-PH versus combined pre-/post-capillary-PH; patients of all groups with concomitant cardiac comorbidities; severe [> 5 WU] versus non-severe PH). This comprehensive study with real-world data from 15 PH-centers showed that PAH-designed risk scores possess predictive power in a large PH cohort, whether considered as common group or calculated separately for each PH group (1-4) and various subgroups.

Sections du résumé

BACKGROUND BACKGROUND
Pulmonary hypertension (PH) is a heterogeneous disease with poor prognosis. Accurate risk stratification is essential for guiding treatment decisions in pulmonary arterial hypertension (PAH). While various risk models were developed for PAH, their comparative prognostic potential requires further exploration. Additionally, the applicability of risk scores in PH groups beyond group 1 remains to be investigated.
RESEARCH QUESTION OBJECTIVE
Are risk scores originally developed for PAH predictive in PH group 1-4?
STUDY DESIGN AND METHODS METHODS
We conducted a comprehensive analysis of outcomes among incident PH patients enrolled in the multicenter worldwide PVRI-GoDeep meta-registry. Analyses were performed across PH groups 1-4 and further subgroups to evaluate the predictive value of PAH-risk scores, including REVEAL Lite 2, REVEAL 2.0, ESC/ERS 2022, COMPERA 3-strata and COMPERA 4-strata.
RESULTS RESULTS
8565 patients were included in the study, of whom 3537 patients were assigned to group 1 PH while 1807, 1635, and 1586 patients were diagnosed with group 2, group 3, and group 4 PH. Pulmonary hemodynamics were impaired with median mPAP of 42 [33,52]mmHg and PVR of 7 [4,11]WU. All risk scores were prognostic in the entire PH population and in each of the PH groups 1-4. The REVEAL scores, when used as continuous prediction models, possessed the highest statistical prognostic power and granularity; the COMPERA 4-strata risk score provided sub-differentiation of the intermediate-risk group. Similar results were obtained when separately analyzing various subgroups (PH subgroups 1.1, 1.4.1, 1.4.4; 3.1, 3.2; group 2 with isolated post-capillary-PH versus combined pre-/post-capillary-PH; patients of all groups with concomitant cardiac comorbidities; severe [> 5 WU] versus non-severe PH).
INTERPRETATION CONCLUSIONS
This comprehensive study with real-world data from 15 PH-centers showed that PAH-designed risk scores possess predictive power in a large PH cohort, whether considered as common group or calculated separately for each PH group (1-4) and various subgroups.

Identifiants

pubmed: 38508334
pii: S0012-3692(24)00309-X
doi: 10.1016/j.chest.2024.03.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Tobiah Antoine (T)
Achim Backofen (A)
John Cannon (J)
Victoria Damonte (V)
Diego Echazarreta (D)
Christina Eichstaedt (C)
Jean Elwing (J)
Kai Förster (K)
Ekkehard Gruenig (E)
Anne Hilgendorff (A)
Arun Jose (A)
Ernesto Junaeda (E)
Philipp Krieb (P)
Kurt Marquardt (K)
Karen Osborn (K)
Johanna Pepke-Zaba (J)
Ioan Tilea (I)
Andreea Varga (A)

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Athiththan Yogeswaran (A)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany).

Henning Gall (H)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany).

Meike Fünderich (M)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany).

Martin R Wilkins (MR)

National Heart and Lung Institute, Imperial College London (UK).

Luke Howard (L)

National Heart and Lung Institute, Imperial College London (UK).

David G Kiely (DG)

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, University of Sheffield and National Institute for Health and Care Research Sheffield Biomedical Research Centre (UK).

Allan Lawrie (A)

National Heart and Lung Institute, Imperial College London (UK);; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, University of Sheffield and National Institute for Health and Care Research Sheffield Biomedical Research Centre (UK).

Paul M Hassoun (PM)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (USA).

Yuriy Sirenklo (Y)

NSC M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National AMC of Ukraine.

Olena Torbas (O)

NSC M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National AMC of Ukraine.

Andrew J Sweatt (AJ)

Division of Pulmonary, Allergy, and Critical Care, and Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University (USA).

Roham T Zamanian (RT)

Division of Pulmonary, Allergy, and Critical Care, and Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University (USA).

Paul G Williams (PG)

Milpark Netcare Hospital, Johannesburg, South Africa.

Marlize Frauendorf (M)

Milpark Netcare Hospital, Johannesburg, South Africa.

Alexandra Arvanitaki (A)

1(st) Department of Cardiology, Aristotle University of Thessaloniki, Greece.

George Giannakoulas (G)

1(st) Department of Cardiology, Aristotle University of Thessaloniki, Greece.

Khaled Saleh (K)

Cleveland Clinic Abu Dhabi (United Arab Emirates).

Hani Sabbour (H)

Cleveland Clinic Abu Dhabi (United Arab Emirates).

Hector R Cajigas (HR)

Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester (USA).

Robert Frantz (R)

Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester (USA).

Imad Al Ghouleh (I)

University of Pittsburgh (USA).

Stephen Y Chan (SY)

University of Pittsburgh (USA).

Evan Brittain (E)

Vanderbilt University Medical Center, Nashville (USA).

Jeffrey S Annis (JS)

Vanderbilt University Medical Center, Nashville (USA).

Antonella Pepe (A)

Fondazione IRCCS Policlinico S.Matteo, Pavia (Italy).

Stefano Ghio (S)

Fondazione IRCCS Policlinico S.Matteo, Pavia (Italy).

Stylianos Orfanos (S)

Evangelismos Hospital Athens (Greece).

Anastasia Anthi (A)

Evangelismos Hospital Athens (Greece).

Raphael W Majeed (RW)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute of Medical Informatics, RWTH Aachen University, Aachen (Germany).

Jochen Wilhelm (J)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany).

Hossein Ardeschir Ghofrani (HA)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany).

Manuel J Richter (MJ)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany).

Friedrich Grimminger (F)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany).

Sandeep Sahay (S)

Houston Methodist Hospital, Houston (USA).

Khodr Tello (K)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany).

Werner Seeger (W)

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen (Germany);; Institute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI), Giessen (Germany);. Electronic address: Werner.Seeger@innere.med.uni-giessen.de.

Classifications MeSH